Overview
Delivering World-Class Medical Care
India offers world-class haematology care for blood cancers and bone marrow disorders at 60–80% lower cost than Western countries. Our partner BMT centres at Fortis Memorial Research Institute and Max Hospital are equipped with state-of-the-art infrastructure and experienced transplant teams.
Bone Marrow Transplant (both allogeneic and autologous) for leukaemia, lymphoma, multiple myeloma, aplastic anaemia, thalassaemia and sickle cell disease is performed routinely at our partner centres — with outcomes that match international standards.
- 1,500+ successful bone marrow transplants at partner centres
- Allogenic, autologous and haploidentical transplant options
- GVHD prevention and management protocols at par with USA/UK
- Dedicated isolation units with HEPA filtration for transplant patients
- Complete donor matching and HLA typing services available
- Post-transplant follow-up coordinated globally by HeyDocta
Specialised Procedures
Hematology Treatments We Offer
Simple Steps
Online Simple Step
for Appointment
The HeyDocta model ensures every patient is supported by a specialist coordinator and a dedicated case manager. It is rare to navigate the process alone — our team works routinely to guide every step.
If you need any help in booking an appointment, please call us anytime — our team is available 24/7.
Select from our list and go through the doctor's profile. Choose the specialist that fits your dental needs.
Connect instantly with a 24×7 specialist or choose to video visit a particular doctor at your convenience.
FAQ
Frequently Asked Questions
A typical BMT programme requires 60–90 days in India. The transplant itself takes place after 2–3 weeks of conditioning chemotherapy, followed by 4–6 weeks of recovery in the hospital's dedicated BMT unit, and then a further 2–4 weeks of outpatient monitoring before it is safe to travel home.
Yes. HLA typing is performed for all family members. Matched sibling donors provide the best outcomes. If no matched sibling is available, we can arrange haploidentical (half-matched) transplants from parents or children, or search international donor registries for unrelated matched donors.
Success rates vary by disease type, patient age and transplant type. For young patients with leukaemia in first remission receiving matched sibling transplants, our partner centres achieve 60–75% long-term survival — comparable to Western BMT programmes.
